Clinical Research Directory

Inclusion Criteria: 1. Participants must be at least 18 years old. 2. Participants thoroughly understand study procedures, and voluntarily sign the written ICF 3. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1. 4. Expected survival time ≥3 months. 5. Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) \& Other advanced solid tumor 6. Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred 7. The organ function level must meet the prescribed standards 8. All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0) 9. Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug 10. Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit 11. Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose. 12. Participants can communicate well with the Investigator and can complete the study according to the study protocol Exclusion Criteria: 1. Other active malignant tumors occurred within 3 years before the first administration of the study drug 2. Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol 3. Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol 4. Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements 5. Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions 6. Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration 7. Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration 8. Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs 9. Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study 10. Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study 11. Situations that the investigator deems unsuitable for participating in this study